12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NADiA ProsVue: Pivotal trial data

A retrospective U.S. pivotal trial in 392 post-radical prostatectomy patients with PSA levels <100 pg/mL showed that Iris' NADiA ProsVue test had 75% sensitivity and 96.6% specificity for detecting patients with a low...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >